Sergio E Starkstein1, Simone Brockman1. 1. Department of Psychiatry University of Western Australia Fremantle Hospital Perth Western Australia Australia.
Abstract
BACKGROUND: Depression is a frequent psychiatric condition in Parkinson's disease (PD). The treatment of depression has been examined in several randomized controlled trials and meta-analyses, but no clear guidelines are available. METHODS: We carried out a systematic review of pharmacological and non-pharmacological treatments for depression in patients with PD using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. We searched main medical databases up to December 12, 2016, and included randomized controlled trials, patient-control studies, and case series with data on treatment modality, outcome measures, and side effects. RESULTS: Selective serotonergic reuptake inhibitors and tricyclic antidepressants may have efficacy for the treatment of depression in patients with PD, although the evidence is not strong. The antidepressant efficacy of dopamine agonists is still controversial, and initial results were positive for pramipexole but not for rotigotine. Cognitive-behavioral therapy showed promising results in two recent randomized controlled trials, but further evidence is required. Studies using repetitive transcranial magnetic stimulation produced conflicting results, and the efficacy results for this treatment have been inconsistent. On the other hand, electroconclusive therapy produced strong positive results in patients with severe depression, but no randomized controlled trials are available. CONCLUSION: Selective serotonergic reuptake inhibitors and cognitive-behavioral therapy are currently first-line treatments for depression in patients with PD, although the evidence is still weak. The heterogeneity among contributory factors for depression in PD should be considered for the most effective treatment of depression in this condition.
BACKGROUND: Depression is a frequent psychiatric condition in Parkinson's disease (PD). The treatment of depression has been examined in several randomized controlled trials and meta-analyses, but no clear guidelines are available. METHODS: We carried out a systematic review of pharmacological and non-pharmacological treatments for depression in patients with PD using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. We searched main medical databases up to December 12, 2016, and included randomized controlled trials, patient-control studies, and case series with data on treatment modality, outcome measures, and side effects. RESULTS: Selective serotonergic reuptake inhibitors and tricyclic antidepressants may have efficacy for the treatment of depression in patients with PD, although the evidence is not strong. The antidepressant efficacy of dopamine agonists is still controversial, and initial results were positive for pramipexole but not for rotigotine. Cognitive-behavioral therapy showed promising results in two recent randomized controlled trials, but further evidence is required. Studies using repetitive transcranial magnetic stimulation produced conflicting results, and the efficacy results for this treatment have been inconsistent. On the other hand, electroconclusive therapy produced strong positive results in patients with severe depression, but no randomized controlled trials are available. CONCLUSION: Selective serotonergic reuptake inhibitors and cognitive-behavioral therapy are currently first-line treatments for depression in patients with PD, although the evidence is still weak. The heterogeneity among contributory factors for depression in PD should be considered for the most effective treatment of depression in this condition.
Authors: Marie Anne Gebara; Kim L Lipsey; Jordan F Karp; Maureen C Nash; Andrea Iaboni; Eric J Lenze Journal: Am J Geriatr Psychiatry Date: 2014-11-25 Impact factor: 4.105
Authors: Luis Agüera-Ortiz; Rocío García-Ramos; Francisco J Grandas Pérez; Jorge López-Álvarez; José Manuel Montes Rodríguez; F Javier Olazarán Rodríguez; Javier Olivera Pueyo; Carmelo Pelegrin Valero; Jesús Porta-Etessam Journal: Front Psychiatry Date: 2021-02-26 Impact factor: 4.157
Authors: Leslie C Jellen; Mechelle M Lewis; Guangwei Du; Xi Wang; Martha L Escobar Galvis; Stanislaw Krzyzanowski; Colt D Capan; Amanda M Snyder; James R Connor; Lan Kong; Richard B Mailman; Patrik Brundin; Lena Brundin; Xuemei Huang Journal: Sci Rep Date: 2021-12-21 Impact factor: 4.379
Authors: Ji Won Han; Yebin D Ahn; Won-Seok Kim; Cheol Min Shin; Seong Jin Jeong; Yoo Sung Song; Yun Jung Bae; Jong-Min Kim Journal: J Korean Med Sci Date: 2018-11-01 Impact factor: 2.153